1stOncology™: Cancer Intelligence Service – Page 12794 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

ThermoGenesis Holdings To Present At The LD Micro 12th Annual Main Event

On December 5, 2019 ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, reported Chris Xu, Ph.D., Chairman and Chief Executive Officer, will present a company overview at the LD Micro 12th Annual Main Event at the Luxe Sunset Boulevard Hotel in Los Angeles, California on Wednesday, December 11, at 1:20 pm PT (Press release, Thermogenesis, DEC 5, 2019, View Source [SID1234551984]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Management will also be available for one-on-one meetings with qualified investors. Interested parties can register and request meetings through the LD Micro Conference portal or contact Rx Communications to schedule a meeting.

A live webcast of the presentation will be available on the ThermoGenesis website at View Source An archived replay will be available for a period of 90 days after the conference.

Select Medical Corporation Announces Proposal to Commence Offering $625 Million of Senior Notes

On December 5, 2019 Select Medical Holdings Corporation ("Holdings") (NYSE: SEM), reported that Select Medical Corporation ("Select") proposes to commence an offering through a private placement, subject to market and other conditions, of $625 million aggregate principal amount of 6.250% senior notes due 2026 (Press release, Select Medical, DEC 5, 2019, View Source [SID1234551983]). It is anticipated that the notes will be issued as additional notes under the same indenture as Select’s existing $550 million aggregate principal amount of 6.250% senior notes due 2026 that were originally issued on August 1, 2019 and, as such, will form a single series and trade interchangeably with such previously issued notes. The notes will be senior unsecured obligations of Select and will be guaranteed by certain of Select’s subsidiaries.

Select intends to use a portion of the net proceeds of the offering, together with a portion of the proceeds from a proposed incremental term loan, and, if needed, available cash, to make an intercompany loan to Concentra, Inc. ("Concentra"), a joint venture subsidiary of Select, which will use the proceeds from such intercompany loan to repay in full all of Concentra’s outstanding term loans, and to pay related fees and expenses.

The notes and related guarantees are being offered in a private placement, solely to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), or outside the United States to persons other than "U.S. persons" in compliance with Regulation S under the Securities Act. The notes and related guarantees have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

This notice does not constitute an offer to sell the notes, nor a solicitation for an offer to purchase the notes, in any jurisdiction in which such offer or solicitation would be unlawful. Any offer of the notes will be made only by means of a private offering memorandum. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

Screen Therapeutics enters into an immuno-oncology drug development partnership with Immunaccel

On December 5, 2019 Screen Therapeutics LLC reported that is has formed a partnership with Immunaccel to focus on the discovery and development of next generation cancer immunotherapies (Press release, Screen Therapeutics, DEC 5, 2019, View Source [SID1234551982]).

Screen Therapeutics will combine its immunology expertise, capabilities and know-how together with Immunaccel’s IP, know-how and proprietary cell lines to discover next generation cancer therapies targeting stromal interactions in the tumor microenvironment. This transaction is also part of a broader strategy for Immunaccel to leverage its intellectual property (IP) and know-how in developing human relevant translational platforms.

Underlying the company’s programs is a combination of proprietary ex vivo 3D platforms and well characterized human cell lines that enable the simulation of the tumor microenvironment. Screen Therapeutics will leverage these platforms to study the tumor stromal barriers that affect T cell activity and migration of immune cells in tumors.

"With approximately 30-40% of patients not responding to current immunotherapies, it is important to study the stromal factors that contribute to this phenomenon. Together with advanced imaging and complimentary technology platforms, we aim to simulate the various tumor immune microenvironments ex vivo, which will allow us to dissect the cross talk between immune cells, stromal cells and tumors with the goal of identifying novel targets and biomarkers," said Tonya Webb PhD, scientific co-founder on Screen Therapeutics.

"Since our inception, our mission has been to research, develop and advance synergistic translational research platforms to accelerate preclinical development timelines and advance innovative drug candidates into clinical trials," said Vik Subbu, Managing Partner of Equidis Ventures and CEO of Immunaccel. "The applications of ex vivo 3D platforms in cancer drug discovery have tremendous potential in providing human physiological relevance in identifying novel drug targets and biomarkers," he added.

Select Medical Corporation Announces Pricing and Upsizing of its Offering of an Additional $675 million of its 6.250% Senior Notes due 2026

On December 5, 2019 Select Medical Holdings Corporation ("Holdings") (NYSE: SEM), reported that Select Medical Corporation ("Select") has priced its private placement of $675 million aggregate principal amount of its 6.250% senior notes due 2026 (the "Additional Notes") as additional notes under the indenture pursuant to which it previously issued $550 million of 6.250% senior notes due 2026 (Press release, Select Medical, DEC 5, 2019, View Source;300970404.html [SID1234551981]). The offering has been upsized from the previously announced amount of $625 million. The offering is expected to close on December 10, 2019, subject to the satisfaction of customary closing conditions.

The Additional Notes and related guarantees are being offered in a private placement, solely to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), or outside the United States to persons other than "U.S. persons" in compliance with Regulation S under the Securities Act. The Additional Notes and related guarantees have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

This notice does not constitute an offer to sell the notes, nor a solicitation for an offer to purchase the Additional Notes, in any jurisdiction in which such offer or solicitation would be unlawful. Any offer of the Additional Notes will be made only by means of a private offering memorandum. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-LAG-3 Monoclonal Antibody in China

On December 5, 2019 Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, reported that the first patient has been successfully dosed in a Phase I clinical trial (CIBI110A101) of anti-lymphocyte activation gene 3 (LAG-3)recombinant fully human monoclonal antibody drug candidate (IBI110) in China (Press release, Innovent Biologics, DEC 5, 2019, View Source [SID1234551980]).

CIBI110A101 is a phase I clinical study conducted in China to evaluate IBI110 in the treatment of patients with advanced malignancies. The primary objectives of the study are to evaluate the safety, tolerability, and initial anti-tumor efficacy of IBI110, either as monotherapy or in combination with Tyvyt (sintilimab injection), an anti-programmed cell death protein 1 (PD-1) antibody drug. The Phase Ia study will explore the safety, tolerability and efficacy of IBI110 as monotherapy.

IBI110 is a recombinant fully human anti-LAG-3 monoclonal antibody and will provide a brand new clinical solution to cancer patients. IBI110 can directly bind to LAG-3 on the surface of T cells, disturb the interaction between LAG-3 and MHCII, relieve the inhibiting effect of LAG-3 on T cells activation and enhance the anti-tumor immune response of T cells. Furthermore, the combination of anti-LAG-3 and anti-PD-1/PD-L1 may provide synergistic enhancement and improve the anti-tumor efficacy.

Professor Caicun Zhou, director of Oncology Department of Shanghai Pulmonary Hospital, said: "Although immune checkpoint inhibitors have shown gratifying progress in oncology therapy, we still confront many new challenges. With the increasing popularity of anti-PD-1/PD-L1 antibody, some patients have shown resistance to anti-PD-1/PD-L1 therapy. Meanwhile, the efficacy of anti-PD-1/PD-L1 therapy in its initial treatment of patients also needs to be further improved. Therefore, it has great significance to develop the next generation of tumor immune drugs, while LAG-3 is one of the most promising and prospective targets in tumor immunotherapy. We are looking forward to the clinical results of IBI110."

Dr. Hui Zhou, Vice President and Head of Oncology Strategy and Medical Sciences of Innovent, said: "LAG-3 is an important immuno-inhibitory receptor, but there is no approved antibody drug targeting LAG-3 so far. Currently, a series of relevant clinical trials is ongoing abroad, and the preliminary results have shown certain safety and anti-tumor effectiveness of anti-LAG-3 antibody either as monotherapy or combination with anti-PD-1/PD-L1 antibody. Notably, the combination therapies hopefully exhibited synergistic enhancement effect. Therefore, developing drugs targeting LAG-3 may provide more novel, comprehensive and effective treatments for patients. We will evaluate the potential clinical value of IBI110 and its combination therapy, and hope to ultimately benefit more patients."

About IBI110

IBI110 is an innovative IgG4κ recombinant fully human anti-LAG-3 monoclonal antibody developed by Innovent. As class 1 innovative drug, IBI110 can directly bind to LAG-3 and block its interaction with MHCII, thus activate and enhance the anti-tumor immune response of T cells. Furthermore, IBI110 may synergize with anti-PD-1/PD-L1 antibody to improve the anti-tumor efficacy. IBI110 may hopefully exert antitumor activity and delay the drug resistance in the form of monotherapy or combination with Tyvyt (sintilimab injection), which will provide more effective treatments for cancer patients.

About CIBI110A101

CIBI110A101 is a Phase I clinical study conducted in China to evaluate IBI110 in the treatment of patients with advanced malignancies. The primary objectives of the study are to evaluate the safety, tolerability, and initial anti-tumor efficacy of IBI110, either as monotherapy or in combination with Tyvyt (sintilimab injection), an anti-programmed cell death protein 1 (PD-1) antibody drug.